What are the recommendations for administration of vaccines that contain live, attenuated influenza virus (LAIV)?

Updated: Aug 07, 2020
  • Author: Hien H Nguyen, MD, MS; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

ACIP continues to not recommend LAIV for the 2017-2018 season. [97]

In June 2016, CDC’s Advisory Committee on Immunization Practices (ACIP) voted that LAIV (FluMist Quadrivalent) should not be used during the 2016-2017 flu season. This ACIP vote was based on data showing poor or relatively lower effectiveness of LAIV from 2013 through 2016. In late May 2016, preliminary data on the effectiveness of LAIV among children aged 2-17 years during the 2015-2016 season became available from the US Influenza Vaccine Effectiveness (VE) Network. The LAIV VE among study participants in that age group against any flu virus was 3% (95% CI, -49% to 37%). In comparison, IIV (flu shots) had a VE estimate of 63% (95% CI, 52-72%) against any flu virus among children aged 2-17 years. [98]

In February 2012, the US Food and Drug Administration (FDA) approved a quadrivalent form of the nasal spray vaccine (FluMist Quadrivalent) that includes a second B strain, thereby increasing the likelihood of adequate protection against circulating influenza B strains. [6] In December 2012, the FDA approved an intramuscular quadrivalent influenza vaccine (Fluarix Quadrivalent) for use in adults and children aged 3 years or older. [5]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!